Topical minoxidil can cause increased body hair due to systemic absorption, varying by individual skin sensitivity. The user seeks experiences and solutions to prevent this side effect.
Creating a liposomal gel with Pyrilutamide for hair loss to reduce systemic effects, similar to Xyon's gel. The discussion includes concerns about ingredient sourcing and the benefits of targeted topical treatments.
Winlevi is being considered for hair loss by someone who wants to avoid systemic hormonal changes. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
Topical finasteride can reduce scalp DHT as effectively as oral finasteride with fewer systemic effects, but availability is limited. Some users make their own solutions due to limited access.
Topical finasteride is considered safer for the liver than oral finasteride due to less systemic absorption, but regular liver function tests are advised. The user is concerned about liver health due to a history of NAFLD and is exploring topical finasteride as a safer alternative.
Topical finasteride can be as effective as oral finasteride for hair regrowth with fewer systemic side effects, but precise dosing is essential. Combining oral dutasteride with topical finasteride is not recommended due to dutasteride's stronger inhibition.
The conversation discusses the potential benefits of creating a hydrophobic version of finasteride to reduce systemic side effects while maintaining scalp health. It compares this idea to fluridil, which is designed to be hydrophobic and has less systemic absorption.
The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.
Oral minoxidil may be more effective than topical due to uniform distribution and systemic activation, but can cause side effects like puffiness. Adding tretinoin to topical minoxidil can enhance its effectiveness by aiding conversion to its active form.
The conversation is about using distilled water as a solvent for topical finasteride to reduce systemic absorption. The user is considering avoiding ethanol and propylene glycol to achieve this.
The conversation expresses frustration over the lack of clear evidence regarding the effectiveness and systemic impact of topical Dutasteride for hair loss treatment, despite years of discussion. People are criticized for not conducting proper research and for providing contradictory anecdotal claims.
A user is considering switching from oral to topical finasteride to reduce systemic DHT impact and is exploring ethossomal finasteride for better skin penetration and potential hair regrowth. They found ethossomal finasteride in Brazil and are seeking opinions on its effectiveness compared to other topical delivery methods.
Applying minoxidil immediately after microneedling at 0.5mm can cause stinging and potential systemic absorption, so some users prefer to wait 12-24 hours. Others report no issues with immediate application, but caution is advised to avoid irritation and side effects.
PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.
Topical finasteride (P-3074) can inhibit scalp DHT by up to 70%, with some users experiencing systemic absorption similar to oral use. Users discuss varying application frequencies and concentrations, with some noticing side effects when overused.
Clascoterone 5% topical solution shows promise for treating male-pattern hair loss by blocking DHT at the follicle without systemic absorption, potentially offering fewer side effects than oral treatments like finasteride. While results are promising, long-term safety and effectiveness need further study, and it may serve as a starting point for developing more effective treatments.
Topical finasteride can effectively reduce scalp DHT by targeting local enzymes, despite less systemic impact compared to oral forms. Combining oral dutasteride with topical finasteride and minoxidil may enhance hair loss prevention, though evidence of its effectiveness is limited.
The user transitioned from finasteride to RU58841 and oral minoxidil to maintain hair gains while avoiding systemic DHT suppression. They have not experienced increased shedding or side effects since stopping finasteride and hope RU58841 will preserve their hair.
The conversation discusses the need for a localized 5-alpha reductase inhibitor that only affects the scalp without systemic side effects, similar to pyrilutamide's approach. Current treatments like topical liposomal finasteride and dutasteride are mentioned, but concerns about their systemic effects and lack of research are highlighted.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
Topical dutasteride is considered for hair loss, but concerns about systemic absorption and side effects like reduced libido are common. Users have mixed results, with some preferring oral finasteride or dutasteride despite side effects, while others find topical treatments beneficial but challenging.
Using both oral and topical minoxidil is likely safe, but be cautious of increased systemic absorption. The best tretinoin dosage to enhance minoxidil effectiveness is not specified.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
The conversation discusses using a low dose of topical finasteride to achieve hair benefits with minimal systemic exposure. Users share experiences and opinions on dosing, systemic buildup, and side effects of both topical and oral finasteride.
The conversation is about the appropriate wait time to apply topical finasteride after microneedling to prevent it from going systemic. The user is combining finasteride with minoxidil and is unsure whether to wait 24 or 48 hours after microneedling before applying the treatment.
Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.
Using topical finasteride with creatine might help reduce hair loss by targeting local DHT while maintaining normal systemic levels, but results are uncertain without testing. Users report mixed experiences with topical treatments like finasteride, dutasteride, RU58841, and minoxidil, with some seeing regrowth and others experiencing side effects.
A 20-year-old is experiencing hair thinning and is considering Clascoterone and Minoxidil as treatments, avoiding finasteride due to concerns about fertility and hormones. A suggestion was made to use Clascoterone for local DHT targeting and combine it with Minoxidil for maintenance and regrowth while avoiding systemic side effects.